MX2023008662A - Metodos para transducir celulas inmunitarias. - Google Patents
Metodos para transducir celulas inmunitarias.Info
- Publication number
- MX2023008662A MX2023008662A MX2023008662A MX2023008662A MX2023008662A MX 2023008662 A MX2023008662 A MX 2023008662A MX 2023008662 A MX2023008662 A MX 2023008662A MX 2023008662 A MX2023008662 A MX 2023008662A MX 2023008662 A MX2023008662 A MX 2023008662A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- immune cells
- cells
- transducing
- exogenous gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142730P | 2021-01-28 | 2021-01-28 | |
| US202263302225P | 2022-01-24 | 2022-01-24 | |
| PCT/US2022/014247 WO2022165133A1 (en) | 2021-01-28 | 2022-01-28 | Methods for transducing immune cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008662A true MX2023008662A (es) | 2023-08-01 |
Family
ID=80685286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008662A MX2023008662A (es) | 2021-01-28 | 2022-01-28 | Metodos para transducir celulas inmunitarias. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12365873B2 (enExample) |
| EP (1) | EP4284937A1 (enExample) |
| JP (1) | JP2024508223A (enExample) |
| KR (1) | KR20230135593A (enExample) |
| AU (1) | AU2022212090A1 (enExample) |
| CA (1) | CA3204357A1 (enExample) |
| IL (1) | IL303847B1 (enExample) |
| MX (1) | MX2023008662A (enExample) |
| TW (1) | TW202246517A (enExample) |
| WO (1) | WO2022165133A1 (enExample) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US20120201794A1 (en) * | 2009-07-15 | 2012-08-09 | Calimmune Inc. | Dual vector for inhibition of human immunodeficiency virus |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| CN103316356B (zh) | 2012-03-22 | 2016-08-17 | 北京三诺佳邑生物技术有限责任公司 | 一种重组慢病毒载体制剂 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| FR3010720B1 (fr) | 2013-09-16 | 2017-08-11 | Genethon | Procede de production de virus enveloppes |
| FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
| KR20240164967A (ko) | 2014-02-04 | 2024-11-21 | 카이트 파마 인코포레이티드 | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| IL292504B2 (en) * | 2015-10-20 | 2024-01-01 | Kite Pharma Inc | -methods of preparing t cells for t cell therapy |
| CN108884460B (zh) * | 2016-03-19 | 2023-04-28 | 埃克苏马生物技术公司 | 淋巴细胞转导及其扩增调节的方法与组合物 |
| WO2018161064A1 (en) * | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| AU2017240801A1 (en) * | 2016-04-01 | 2018-10-25 | Amgen Inc. | Chimeric receptors to FLT3 and methods of use thereof |
| SG10202107808SA (en) | 2017-01-18 | 2021-08-30 | F1 Oncology Inc | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
| EP3571294A1 (en) | 2017-01-18 | 2019-11-27 | F1 Oncology, Inc. | Methods of transducing and expanding immune cells and uses thereof |
-
2022
- 2022-01-28 US US17/587,138 patent/US12365873B2/en active Active
- 2022-01-28 EP EP22709435.6A patent/EP4284937A1/en active Pending
- 2022-01-28 TW TW111103878A patent/TW202246517A/zh unknown
- 2022-01-28 JP JP2023544092A patent/JP2024508223A/ja active Pending
- 2022-01-28 AU AU2022212090A patent/AU2022212090A1/en active Pending
- 2022-01-28 KR KR1020237025863A patent/KR20230135593A/ko active Pending
- 2022-01-28 CA CA3204357A patent/CA3204357A1/en active Pending
- 2022-01-28 MX MX2023008662A patent/MX2023008662A/es unknown
- 2022-01-28 WO PCT/US2022/014247 patent/WO2022165133A1/en not_active Ceased
- 2022-01-28 IL IL303847A patent/IL303847B1/en unknown
-
2025
- 2025-06-17 US US19/241,275 patent/US20260009000A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024508223A (ja) | 2024-02-26 |
| EP4284937A1 (en) | 2023-12-06 |
| CA3204357A1 (en) | 2022-08-04 |
| US20260009000A1 (en) | 2026-01-08 |
| US12365873B2 (en) | 2025-07-22 |
| IL303847A (en) | 2023-08-01 |
| IL303847B1 (en) | 2026-06-01 |
| KR20230135593A (ko) | 2023-09-25 |
| US20220249556A1 (en) | 2022-08-11 |
| AU2022212090A1 (en) | 2023-07-06 |
| TW202246517A (zh) | 2022-12-01 |
| WO2022165133A1 (en) | 2022-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125057T1 (el) | Anti-cd277 αντισωματα και χρησεις αυτων | |
| Shah et al. | Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity | |
| BR112023014980A2 (pt) | Lentivírus para gerar células que expressam o receptor de antígeno quimérico anti-cd19 | |
| MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| MX2019006438A (es) | Produccion de celulas modificadas para terapia de celulas adoptivas. | |
| CL2021002249A1 (es) | Composiciones de partículas de sílice mesoporosa para administración viral | |
| CL2020003343A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de los mismos para la introducción dirigida de material genético a células humanas (divisional de la solicitud 201903842) | |
| MX382541B (es) | Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva. | |
| MX2020001490A (es) | Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas. | |
| CO2020008972A2 (es) | Nanopartícula de lípido que contiene ácido nucleico y uso de la misma | |
| MX2022015062A (es) | Nuevas construcciones para receptores de antígenos quiméricos. | |
| WO2016044605A8 (en) | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy | |
| MX2020006689A (es) | Composiciones de vcar y metodos de uso. | |
| MX2021010320A (es) | Administracion de biomoleculas a celulas mononucleares de sangre periferica (pbmc) para modificar una respuesta inmunitaria. | |
| BR112015019950A2 (pt) | Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro | |
| MX2018001568A (es) | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. | |
| MX2018005274A (es) | Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. | |
| MX2013010793A (es) | Metodo y composiciones para inmunoterapia celular. | |
| EP4394032A3 (en) | Methods for producing autologous t cells useful to treat cancers and compositions thereof | |
| MX2019011897A (es) | Celulas efectoras inmunitarias especificas de antigenos. | |
| CL2018002140A1 (es) | Métodos y composiciones para aumentar la eficiencia de modificación genética dirigida usando reparación genética mediada por oligonucleótidos | |
| CR20200460A (es) | Suministro intracelular de biomeléculas para modificar respuestas inmunes | |
| WO2015120096A3 (en) | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof | |
| AR101400A1 (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido | |
| MX2020012744A (es) | Metodo y composiciones para inmunoterapia celular. |